Amyloid-related biomarkers and axonal damage proteins in parkinsonian syndromes.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Parkinsonism & Related Disorders

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.parkreldis.2011.08.012PMID 21873100
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Inter-laboratory variation in cerebrospinal fluid biomarkers for Alzheimer's disease: united we stand, divided we fall

  2010cited by this paper
• Soluble amyloid precursor proteins in the cerebrospinal fluid as novel potential biomarkers of Alzheimer's disease: a multicenter study

  2010cited by this paper
• Levels of brain related proteins in cerebrospinal fluid: an aid in the differential diagnosis of parkinsonian disorders.

  2009influential reference
• Second consensus statement on the diagnosis of multiple system atrophy

  2008cited by this paper
• O3‐02–06: Elevated cerebrospinal fluid BACE1 activity in incipient Alzheimer's disease

  2008cited by this paper
• Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria.

  2007cited by this paper
• Diagnosis and management of dementia with Lewy bodies

  2005cited by this paper
• SIC Task Force appraisal of clinical diagnostic criteria for parkinsonian disorders

  2003cited by this paper
• Decreased CSF amyloid &bgr;42 and normal tau levels in dementia with Lewy bodies

  2000cited by this paper
• Patients with Amyotrophic Lateral Sclerosis and Other Neurodegenerative Diseases Have Increased Levels of Neurofilament Protein in CSF

  1996cited by this paper
• Neurofilament gene expression: a major determinant of axonal caliber.

  1987cited by this paper

• Somatic CAG repeat expansion in blood associates with biomarkers of neurodegeneration in Huntington’s disease decades before clinical motor diagnosis

  2025cites this paper
• Differentiating Progressive Supranuclear Palsy and Corticobasal Syndrome: Insights from Cerebrospinal Fluid Biomarkers—A Narrative Review

  2025cites this paper
• Fluid biomarkers in atypical Parkinsonism: current state and future perspectives

  2025cites this paper
• Biomarkers for Lewy body diseases and other alpha-synucleinopathies in biofluids: current evidence and future directions

  2025cites this paper
• Neurofilament Light Chain in Cerebrospinal Fluid and Blood in Multiple System Atrophy: A Systematic Review and Meta-Analysis

  2025cites this paper
• Multiple system atrophy

  2024cites this paper
• Salivary biomarkers for the molecular diagnosis of Dementia with Lewy Bodies

  2024cites this paper
• CSF biomarkers for predicting phenoconversion in patients with isolated REM sleep behaviour disorder.

  2023cites this paper
• Parkinson's disease fluid biomarkers for differential diagnosis of atypical parkinsonian syndromes

  2022cites this paper
• Progress regarding the context-of-use of tau as biomarker of Alzheimer’s disease and other neurodegenerative diseases

  2021cites this paper
• Laboratory‐Supported Multiple System Atrophy beyond Autonomic Function Testing and Imaging: A Systematic Review by the MoDiMSA Study Group

  2021cites this paper
• Molecular profiling in Parkinsonian syndromes: CSF biomarkers.

  2020cites this paper
• Contactin-1 Is Reduced in Cerebrospinal Fluid of Parkinson’s Disease Patients and Is Present within Lewy Bodies

  2020cites this paper
• An update on blood-based biomarkers for non-Alzheimer neurodegenerative disorders

  2020cites this paper
• Diagnostic utility of fluid biomarkers in multiple system atrophy: a systematic review and meta-analysis

  2020cites this paper
• Title : An update on blood-based biomarkers for non-Alzheimer neurodegenerative disorders

  2019cites this paper
• Four-repeat tauopathies.

  2019cites this paper
• CSF Biomarkers for Early Diagnosis of Synucleinopathies: Focus on Idiopathic RBD

  2019cites this paper
• Serum neurofilament light chain in progressive supranuclear palsy.

  2018cites this paper
• Fluid Biomarkers in Alzheimer’s Disease and Frontotemporal Dementia

  2018cites this paper
• Cerebrospinal fluid NFL in the differential diagnosis of parkinsonian disorders: A meta-analysis.

  2018cites this paper
• Potential clinical utility of multiple system atrophy biomarkers

  2017cites this paper
• Tracking and predicting disease progression in progressive supranuclear palsy: CSF and blood biomarkers

  2017cites this paper
• Cerebrospinal fluid levels of neurofilament light chain in multiple system atrophy relative to Parkinson’s disease: a meta-analysis

  2017cites this paper
• Biomarkers in cerebrospinal fluid for synucleinopathies, tauopathies, and other neurodegenerative disorders.

  2017cites this paper
• Cerebrospinal fluid biomarkers for Parkinson's disease – a systematic review

  2017cites this paper
• Advances in neuroimaging in frontotemporal dementia

  2016cites this paper
• “New Old Pathologies”: AD, PART, and Cerebral Age-Related TDP-43 With Sclerosis (CARTS)

  2016cites this paper
• Biological confounders for the values of cerebrospinal fluid proteins in Parkinson's disease and related disorders

  2016cites this paper
• Detection of proteolytic signatures for Parkinson's disease

  2016cites this paper
• Neurochemical biomarkers in the diagnosis of frontotemporal lobar degeneration: an update

  2016cites this paper
• Cerebrospinal fluid proteomics and protein biomarkers in frontotemporal lobar degeneration: Current status and future perspectives.

  2015cites this paper
• Fluid biomarkers in multiple system atrophy: A review of the MSA Biomarker Initiative.

  2015cites this paper
• CSF Neurofilament Light Chain but not FLT3 Ligand Discriminates Parkinsonian Disorders

  2015cites this paper
• Heteromers of amyloid precursor protein in cerebrospinal fluid

  2015cites this paper
• A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes

  2015cites this paper
• CSF Neurofilament Light Chain but not FLT3 Ligand Discriminates Parkinsonian Disorders

  2015cites this paper
• Les marqueurs biologiques de l'atrophie multisystématisée

  2014influential citation
• Cerebrospinal fluid α-synuclein in the differential diagnosis of parkinsonian syndromes

  2014cites this paper
• Cerebrospinal Fluid Biomarkers in Alzheimer’s Disease and Frontotemporal Dementia

  2014cites this paper
• What is the Clinical Significance of Cerebrospinal Fluid Biomarkers in Parkinson's disease? Is the Significance Diagnostic or Prognostic?

  2014cites this paper
• Diagnosing Progressive Supranuclear Palsy: Role of Biological and Neuroimaging Markers

  2014cites this paper
• Cerebrospinal fluid biomarkers in parkinsonian conditions: an update and future directions

  2014cites this paper
• An update on the cerebellar subtype of multiple system atrophy

  2014cites this paper
• Cerebrospinal Fluid Biomarker Candidates for Parkinsonian Disorders

  2013cites this paper
• Cerebrospinal fluid biomarkers in Parkinson disease

  2013cites this paper
• Cerebrospinal fluid neurofilament light chain protein levels in subtypes of frontotemporal dementia

  2013cites this paper
• Recent developments in biomarkers in Parkinson disease

  2013cites this paper
• Acrylamide alters cytoskeletal protein level in rat serum.

  2013cites this paper
• Approach to Cerebrospinal Fluid (CSF) Biomarker Discovery and Evaluation in HIV Infection

  2013cites this paper
• C URRENT OPINION Atypical parkinsonism: an update

  2013cites this paper
• Atypical parkinsonism: an update

  2013cites this paper
• Cerebrospinal fluid biomarkers for clinical trials: why markers for differential diagnosis are important.

  2012cites this paper